Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
NCT ID: NCT03972046
Last Updated: 2020-10-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE2
Study Classification
INTERVENTIONAL
Study Start Date
2019-06-24
Study Completion Date
2020-02-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will investigate whether the use of talimogene laherparepvec (T-VEC) in combination with BRAF/MEK inhibitor will result in durable regional and distant recurrence free survival in the neoadjuvant setting for treatment of advanced nodal BRAF mutant melanoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
NCT03088176
Melanoma
BRAF Gene Mutation
UNKNOWN
PHASE1
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
NCT01584648
Melanoma
COMPLETED
PHASE3
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
NCT01701037
Recurrent Melanoma
Stage IIB Melanoma (Locally Advanced)
Stage IIC Melanoma (Locally Advanced)
+4 more
TERMINATED
PHASE2
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
NCT03069378
Sarcoma
Epithelioid Sarcoma
Cutaneous Angiosarcoma
ACTIVE_NOT_RECRUITING
PHASE2
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
NCT02427893
Melanoma
WITHDRAWN
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective, non-randomized, open-label, single-center interventional study looking at the response rate when using talimogene laherparepvec (T-VEC) in combination with BRAF/MEK inhibitor in neoadjuvant setting for treatment of advanced nodal BRAF mutant melanoma. For this pilot study, a sample size of 20 participants, over 18 years of age will be included.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Melanoma (Skin)
Melanoma Stage IIIb-IVM1a
Metastasis Skin
Tumor Skin
BRAF Gene Mutation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Patients, aged 18+, seen at the TriHealth Cancer Institute and/or TriHealth Surgical Institute with a palpable regional melanoma metastasis at the time of initial presentation or with regional recurrence and tumors with a BRAF mutation will be considered for participation in this study.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T-Vec + BRAF/MEK
Participants will begin taking the following 3 medications:
BRAF Inhibitor dabrafenib 150 mg by mouth twice a day; MEK inhibitor trametinib 2 mg by mouth once a day; Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection (Dose #1: 10\^6 PFU/mL; Dose #2: 10\^8 PFU/mL 21 (+3) days after first dose; Subsequent doses: 10\^8 PFU/mL every 14 (+/-3) days).
Dosing to continue for at least 3 months, or up to 6 months if no plateau in response.
May stop earlier than 3 months at physician discretion depending on side effects and response.
Ultrasound of tumor nodal basin(s) monthly.
Labs every 4 weeks: CBC with differential, CMP, LDH CT of chest/abdomen/pelvis every 3 months.
PET CT or brain MRI as needed at discretion of the investigator.
Manual tumor measurement in office prior to each injection.
Group Type
EXPERIMENTAL
Talimogene laherparepvec (T-Vec)
Intervention Type
DRUG
Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
Dabrafenib (BRAF Inhibitor)
Intervention Type
DRUG
Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
Trametinib (MEK Inhibitor)
Intervention Type
DRUG
Trametinib (MEK Inhibitor) 2 mg by mouth once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Talimogene laherparepvec (T-Vec)
Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
Intervention Type
DRUG
Dabrafenib (BRAF Inhibitor)
Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
Intervention Type
DRUG
Trametinib (MEK Inhibitor)
Trametinib (MEK Inhibitor) 2 mg by mouth once a day
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18
* Malignant melanoma Stage IIIb-IVM1a patients.
* Primary or recurrent disease.
* Cutaneous primary melanoma or unknown primary.
* Measurable disease as evidenced by:
* At least one lesion measuring greater than or equal to 10 mm on CT, ultrasound, or physical exam
* A conglomerate of superficial lesions measuring which in aggregate have a total diameter of 10 mm
* Injectable disease
* Palpable regional metastasis at the time of initial presentation or with regional recurrence
* Tumor(s) with BRAF mutation
* ECOG 0,1,2
* Life expectancy \> 2 years in the opinion of the investigator
* Able to provide written informed consent
* Adequate organ function based on most recent labs (according to investigator discretion), defined as follows:
* Hematological: Absolute neutrophil count ≥ 1500/mm3 (1.5x109/L); Platelet count ≥ 75,000/mm3 (7.5x109/L); Hemoglobin ≥ 8 g/dL (without need for hematopoietic growth factor or transfusion support)
* Renal: Serum creatinine ≤ 1.5 x upper limit of normal (ULN), OR 24-hour creatinine clearance ≥ 60 mL/min for subject with creatinine levels \> 1.5 x ULN. (Note: Creatinine clearance need not be determined if the baseline serum creatinine is ≤ 1.5 x ULN. . Creatinine clearance should be determined per institutional standard).
* Hepatic: Serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with total bilirubin level \> 1.5 x ULN; Aspartate aminotransferase (AST) ≤ 2.5 x ULN OR ≤ 5 x ULN, if liver metastases present and injection does not involve a visceral lesion; Alanine aminotransferase (ALT) ≤ 2.5 x ULN OR ≤ 5 x ULN, if liver metastases present and injection does not involve a visceral lesion
* Coagulation: International normalization ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN, unless the subject is receiving anticoagulant therapy, in which case PT and partial thromboplastin time (PTT)/ activated PTT (aPTT) must be within therapeutic range of intended use of anticoagulants; PTT or aPTT ≤ 1.5 x ULN, unless the subject is receiving anticoagulant therapy as long as PT and PTT/aPTT is within therapeutic range of intended use of anticoagulants.
* Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to enrollment. If urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Exclusion
* BRAF wild type tumor
* M1b and M1c disease
* Clinically active cerebral metastases, bony metastases, visceral metastases
* Mucosal or ocular primary disease
* Known active central nervous system (CNS) metastases. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids \>10 mg/day of prednisone or equivalent. The exception does not include carcinomatosus meningitis which is excluded regardless of clinical stability.
* History or evidence of active autoimmune disease that requires systemic treatment (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
* Evidence of clinically significant immunosuppression such as the following:
* Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease.
* Concurrent opportunistic infection.
* Receiving systemic immunosuppressive therapy (\> 2 weeks) including oral steroid doses \> 10 mg/day of prednisone or equivalent within 7 days prior to enrollment.
* Active herpetic skin lesions or prior complications of HSV-1 infection (e.g., herpetic keratitis or encephalitis).
* Requires intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use.
* Previous treatment with talimogene laherparepvec or any other oncolytic virus.
* Previous treatment with a BRAF or MEK inhibitor
* Prior therapy with tumor vaccine.
* Received live vaccine within 28 days prior to enrollment.
* Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment. Adjuvant hormonal therapy is allowed if appropriate for planned study.
* Prior radiotherapy in which the field does not overlap the injection sites or non-immunosuppressive targeted therapy within 14 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 14 days prior to enrollment
* Currently receiving treatment with another investigational device or drug study, or \< 28 days since ending treatment with another investigational device or drug study(s).
* Other investigational procedures while participating in this study are excluded.
* Known to have acute or chronic active hepatitis B infection.
* Known to have acute or chronic active hepatitis C infection.
* Known to have human immunodeficiency virus (HIV) infection.
* History of other malignancy within the past 5 years with the following exceptions:
* Adequately treated non melanoma skin cancer without evidence of disease at the time of enrollment
* Adequately treated cervical carcinoma in situ without evidence of disease at the time of enrollment
* Adequately treated breast ductal carcinoma in situ without evidence of disease at the time of enrollment
* Prostatic intraepithelial neoplasia without evidence of prostate cancer at the time of enrollment.
* Subject has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing.
* Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec.
* Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec.
* Subjects who are unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for HSV-1 induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or infants under the age of 3 months, during talimogene laherparepvec treatment and through 30 days after the last dose of talimogene laherparepvec.
* Malignant melanoma Stage IIIb-IVM1a patients.
* Primary or recurrent disease.
* Cutaneous primary melanoma or unknown primary.
* Measurable disease as evidenced by:
* At least one lesion measuring greater than or equal to 10 mm on CT, ultrasound, or physical exam
* A conglomerate of superficial lesions measuring which in aggregate have a total diameter of 10 mm
* Injectable disease
* Palpable regional metastasis at the time of initial presentation or with regional recurrence
* Tumor(s) with BRAF mutation
* ECOG 0,1,2
* Life expectancy \> 2 years in the opinion of the investigator
* Able to provide written informed consent
* Adequate organ function based on most recent labs (according to investigator discretion), defined as follows:
* Hematological: Absolute neutrophil count ≥ 1500/mm3 (1.5x109/L); Platelet count ≥ 75,000/mm3 (7.5x109/L); Hemoglobin ≥ 8 g/dL (without need for hematopoietic growth factor or transfusion support)
* Renal: Serum creatinine ≤ 1.5 x upper limit of normal (ULN), OR 24-hour creatinine clearance ≥ 60 mL/min for subject with creatinine levels \> 1.5 x ULN. (Note: Creatinine clearance need not be determined if the baseline serum creatinine is ≤ 1.5 x ULN. . Creatinine clearance should be determined per institutional standard).
* Hepatic: Serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with total bilirubin level \> 1.5 x ULN; Aspartate aminotransferase (AST) ≤ 2.5 x ULN OR ≤ 5 x ULN, if liver metastases present and injection does not involve a visceral lesion; Alanine aminotransferase (ALT) ≤ 2.5 x ULN OR ≤ 5 x ULN, if liver metastases present and injection does not involve a visceral lesion
* Coagulation: International normalization ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN, unless the subject is receiving anticoagulant therapy, in which case PT and partial thromboplastin time (PTT)/ activated PTT (aPTT) must be within therapeutic range of intended use of anticoagulants; PTT or aPTT ≤ 1.5 x ULN, unless the subject is receiving anticoagulant therapy as long as PT and PTT/aPTT is within therapeutic range of intended use of anticoagulants.
* Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to enrollment. If urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Exclusion
* BRAF wild type tumor
* M1b and M1c disease
* Clinically active cerebral metastases, bony metastases, visceral metastases
* Mucosal or ocular primary disease
* Known active central nervous system (CNS) metastases. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids \>10 mg/day of prednisone or equivalent. The exception does not include carcinomatosus meningitis which is excluded regardless of clinical stability.
* History or evidence of active autoimmune disease that requires systemic treatment (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
* Evidence of clinically significant immunosuppression such as the following:
* Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease.
* Concurrent opportunistic infection.
* Receiving systemic immunosuppressive therapy (\> 2 weeks) including oral steroid doses \> 10 mg/day of prednisone or equivalent within 7 days prior to enrollment.
* Active herpetic skin lesions or prior complications of HSV-1 infection (e.g., herpetic keratitis or encephalitis).
* Requires intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use.
* Previous treatment with talimogene laherparepvec or any other oncolytic virus.
* Previous treatment with a BRAF or MEK inhibitor
* Prior therapy with tumor vaccine.
* Received live vaccine within 28 days prior to enrollment.
* Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment. Adjuvant hormonal therapy is allowed if appropriate for planned study.
* Prior radiotherapy in which the field does not overlap the injection sites or non-immunosuppressive targeted therapy within 14 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 14 days prior to enrollment
* Currently receiving treatment with another investigational device or drug study, or \< 28 days since ending treatment with another investigational device or drug study(s).
* Other investigational procedures while participating in this study are excluded.
* Known to have acute or chronic active hepatitis B infection.
* Known to have acute or chronic active hepatitis C infection.
* Known to have human immunodeficiency virus (HIV) infection.
* History of other malignancy within the past 5 years with the following exceptions:
* Adequately treated non melanoma skin cancer without evidence of disease at the time of enrollment
* Adequately treated cervical carcinoma in situ without evidence of disease at the time of enrollment
* Adequately treated breast ductal carcinoma in situ without evidence of disease at the time of enrollment
* Prostatic intraepithelial neoplasia without evidence of prostate cancer at the time of enrollment.
* Subject has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing.
* Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec.
* Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec.
* Subjects who are unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for HSV-1 induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or infants under the age of 3 months, during talimogene laherparepvec treatment and through 30 days after the last dose of talimogene laherparepvec.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TriHealth Cancer Institute
UNKNOWN
Sponsor Role
collaborator
TriHealth Surgical Institute
UNKNOWN
Sponsor Role
collaborator
TriHealth Ultrasound Department
UNKNOWN
Sponsor Role
collaborator
Bethesda North TriHealth Hospital
UNKNOWN
Sponsor Role
collaborator
Good Samaritan TriHealth Hospital
UNKNOWN
Sponsor Role
collaborator
TriHealth Inc.
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TriHealth Cancer Institute - Kenwood
Cincinnati, Ohio, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
Reference Type
BACKGROUND
Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, Chen L, Shilkrut M, Kaufman HL. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Ann Surg Oncol. 2016 Dec;23(13):4169-4177. doi: 10.1245/s10434-016-5286-0. Epub 2016 Jun 24.
Reference Type
BACKGROUND
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
Reference Type
BACKGROUND
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
Reference Type
BACKGROUND
Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr;14(4):450-73. doi: 10.6004/jnccn.2016.0051.
Reference Type
BACKGROUND
Thiam A, Zhao Z, Quinn C, Barber B. Years of life lost due to metastatic melanoma in 12 countries. J Med Econ. 2016;19(3):259-64. doi: 10.3111/13696998.2015.1115764. Epub 2015 Nov 25.
Reference Type
BACKGROUND
Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011 Feb 24;364(8):772-4. doi: 10.1056/NEJMcibr1013704. No abstract available.
Reference Type
BACKGROUND
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25.
Reference Type
BACKGROUND
Johnson AS, Crandall H, Dahlman K, Kelley MC. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. J Am Coll Surg. 2015 Apr;220(4):581-93.e1. doi: 10.1016/j.jamcollsurg.2014.12.057. Epub 2015 Jan 30.
Reference Type
BACKGROUND
Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Semin Oncol. 2016 Dec;43(6):638-646. doi: 10.1053/j.seminoncol.2016.10.005. Epub 2016 Oct 27.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20177504
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
17-086
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
NCT02196181
ACTIVE_NOT_RECRUITING
PHASE2
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
NCT02263898
WITHDRAWN
PHASE2
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
NCT02296112
COMPLETED
PHASE2
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
NCT01597908
COMPLETED
PHASE3
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
NCT00349206
COMPLETED
PHASE1
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
NCT01495988
TERMINATED
PHASE2
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
NCT05868629
RECRUITING
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
NCT01625156
COMPLETED
PHASE1
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
NCT00602576
COMPLETED
PHASE2
TVEC and Preop Radiation for Sarcoma (4 ml Dose)
NCT02453191
COMPLETED
PHASE1/PHASE2
A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
NCT00733798
TERMINATED
PHASE1/PHASE2
T-VEC in Non-melanoma Skin Cancer
NCT03458117
COMPLETED
PHASE1
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02097225
TERMINATED
PHASE1
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
NCT01851408
WITHDRAWN
PHASE2
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT01548482
COMPLETED
PHASE1
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
NCT02567396
WITHDRAWN
PHASE1
Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma
NCT00030589
UNKNOWN
PHASE2
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
NCT02014441
COMPLETED
PHASE2
Special Drug Use-results Surveillance of Tafinlar/Mekinist
NCT06262919
RECRUITING
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
NCT00538005
UNKNOWN
PHASE1/PHASE2
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
NCT01619774
COMPLETED
PHASE2
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
NCT01436565
COMPLETED
PHASE1
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
NCT01531361
COMPLETED
PHASE1
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
NCT00111007
COMPLETED
PHASE3
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
NCT07121829
TERMINATED
PHASE1